
primary studies - published RCT

Glutamine supplementation in cystic fibrosis: A randomized placebo-controlled trial.

Code: PM26709241

Year: 2015 **Date:** 2020

Author: Forrester DL

Study design (if review, criteria of inclusion for studies)

Phase 3 randomized double blind controlled, trial

Participants

238 people with cystic fibrosis (CF) and at least one nonsense mutation (nmCF)

Interventions

Ataluren. 48 weeks

Outcome measures

Independent scoring systems to characterize structural lung disease. Perth-Rotterdam Annotated Grid Morphometric Analysis for CF (PRAGMA-CF) scoring systems. CF-CT and PRAGMA-CF subscores were expressed as %maximal score and %total lung volume, respectively.

Main results

PRAGMA-CF subscores %Disease ($p = 0.008$) and %Mucus Plugging ($p = 0.029$) progressed over 48 weeks. CF-CT subscores did not show progression. There was no difference in progression of structural lung disease between treatment arm and placebo independent of tobramycin use.

Authors' conclusions

PRAGMA-CF Chest CT scores can be used as an outcome measure to study the effect of potential disease modifying drugs in CF on lung structure.

<http://dx.doi.org/10.1002/ppul.23370>

See also

Pediatr Pulmonol. 2015 Dec 27. doi: 10.1002/ppul.23370.

Keywords

PTC124; Ataluren; CFTR Modulators; pharmacological_intervention;